FEATURED COMPANIES
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- MORE
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Neglected Tropical Disease Treatment Market: About this market
Neglected tropical diseases are caused by pathogens such as parasites, bacteria, and virus. The neglected tropical disease treatment market considers the treatment of neglected tropical diseases using antiparasitic drugs, antibacterial drugs, and antiviral drugs. Our analysis also considers growth opportunities in Asia, North America, and ROW. In 2018, the antiparasitic drugs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of parasite-infected diseases will play a significant role in the antiparasitic drugs segment to maintain its market position. Also, our global neglected tropical disease treatment market report looks at factors such as initiatives to increase awareness and access to medicines for neglected tropical diseases, high morbidity rates, and increased funding in R&D. However, challenges associated with diagnosing neglected tropical diseases, challenges associated with drug discovery for neglected tropical diseases, and the increase in drug resistance may hamper the growth of the neglected tropical disease treatment industry over the forecast period.
Global Neglected Tropical Disease Treatment Market: Overview
Initiatives to increase awareness and access to medicines for neglected tropical diseases
The growing prevalence of neglected tropical diseases in tropical and subtropical countries has led many organizations across the world to increase awareness and to ensure easy availability of drugs for the treatment of such diseases. For instance, the Global Buruli Ulcer initiative by the World Health Organization (WHO) is aimed at improving awareness about Buruli ulcer disease. Several other organizations across the world are taking initiatives to improve the access of medicines, vaccines, and diagnostics for the treatment of neglected tropical diseases in low and middle-income countries. These developments are expected to drive the growth of the global neglected tropical disease treatment market size at a CAGR of almost 5% during the forecast period.
Development and approval of therapeutics for neglected tropical diseases
The high incidence of neglected tropical diseases such as dengue, lymphatic filariasis, trachoma, and leishmaniasis have encouraged researchers to focus on developing therapeutics for such diseases. For instance, researchers at the University Hospitals Cleveland Medical Center have developed a drug to treat patients with lymphatic filariasis. The drug is currently in Phase II of clinical trials. Many such advancements in drug development will aid in the treatment of many neglected tropical diseases and also fuel the market’s growth.
Competitive Landscape
With the presence of a few players, the global neglected tropical disease treatment market is fairly concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading drug manufacturers, that include Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, and Pfizer Inc.
Also, the neglected tropical disease treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Neglected tropical diseases are caused by pathogens such as parasites, bacteria, and virus. The neglected tropical disease treatment market considers the treatment of neglected tropical diseases using antiparasitic drugs, antibacterial drugs, and antiviral drugs. Our analysis also considers growth opportunities in Asia, North America, and ROW. In 2018, the antiparasitic drugs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing prevalence of parasite-infected diseases will play a significant role in the antiparasitic drugs segment to maintain its market position. Also, our global neglected tropical disease treatment market report looks at factors such as initiatives to increase awareness and access to medicines for neglected tropical diseases, high morbidity rates, and increased funding in R&D. However, challenges associated with diagnosing neglected tropical diseases, challenges associated with drug discovery for neglected tropical diseases, and the increase in drug resistance may hamper the growth of the neglected tropical disease treatment industry over the forecast period.
Global Neglected Tropical Disease Treatment Market: Overview
Initiatives to increase awareness and access to medicines for neglected tropical diseases
The growing prevalence of neglected tropical diseases in tropical and subtropical countries has led many organizations across the world to increase awareness and to ensure easy availability of drugs for the treatment of such diseases. For instance, the Global Buruli Ulcer initiative by the World Health Organization (WHO) is aimed at improving awareness about Buruli ulcer disease. Several other organizations across the world are taking initiatives to improve the access of medicines, vaccines, and diagnostics for the treatment of neglected tropical diseases in low and middle-income countries. These developments are expected to drive the growth of the global neglected tropical disease treatment market size at a CAGR of almost 5% during the forecast period.
Development and approval of therapeutics for neglected tropical diseases
The high incidence of neglected tropical diseases such as dengue, lymphatic filariasis, trachoma, and leishmaniasis have encouraged researchers to focus on developing therapeutics for such diseases. For instance, researchers at the University Hospitals Cleveland Medical Center have developed a drug to treat patients with lymphatic filariasis. The drug is currently in Phase II of clinical trials. Many such advancements in drug development will aid in the treatment of many neglected tropical diseases and also fuel the market’s growth.
Competitive Landscape
With the presence of a few players, the global neglected tropical disease treatment market is fairly concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading drug manufacturers, that include Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, and Pfizer Inc.
Also, the neglected tropical disease treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
List of Exhibits
Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Diseases caused by organisms
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Antiparasitic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antiparasitic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antibacterial drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antibacterial drugs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Antiviral drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Antiviral drugs - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bayer AG - Vendor overview
Exhibit 45: Bayer AG - Business segments
Exhibit 46: Bayer AG - Organizational developments
Exhibit 47: Bayer AG - Geographic focus
Exhibit 48: Bayer AG - Segment focus
Exhibit 49: Bayer AG - Key offerings
Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 56: GlaxoSmithKline Plc - Vendor overview
Exhibit 57: GlaxoSmithKline Plc - Business segments
Exhibit 58: GlaxoSmithKline Plc - Organizational developments
Exhibit 59: GlaxoSmithKline Plc - Geographic focus
Exhibit 60: GlaxoSmithKline Plc - Segment focus
Exhibit 61: GlaxoSmithKline Plc - Key offerings
Exhibit 62: Novartis AG - Vendor overview
Exhibit 63: Novartis AG - Business segments
Exhibit 64: Novartis AG - Organizational developments
Exhibit 65: Novartis AG - Geographic focus
Exhibit 66: Novartis AG - Segment focus
Exhibit 67: Novartis AG - Key offerings
Exhibit 68: Pfizer Inc. - Vendor overview
Exhibit 69: Pfizer Inc. - Business segments
Exhibit 70: Pfizer Inc. - Organizational developments
Exhibit 71: Pfizer Inc. - Geographic focus
Exhibit 72: Pfizer Inc. - Segment focus
Exhibit 73: Pfizer Inc. - Key offerings
Exhibit 74: Validation techniques employed for market sizing
Exhibit 75: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by type
- Comparison by type
- Antiparasitic drugs - Market size and forecast 2018-2023
- Antibacterial drugs - Market size and forecast 2018-2023
- Antiviral drugs - Market size and forecast 2018-2023
- Market opportunity by type
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- ROW - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- North America - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Market trends
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Diseases caused by organisms
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Antiparasitic drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Antiparasitic drugs - Year-over-year growth 2019-2023 (%)
Exhibit 22: Antibacterial drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Antibacterial drugs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Antiviral drugs - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Antiviral drugs - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Impact of drivers and challenges
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Bayer AG - Vendor overview
Exhibit 45: Bayer AG - Business segments
Exhibit 46: Bayer AG - Organizational developments
Exhibit 47: Bayer AG - Geographic focus
Exhibit 48: Bayer AG - Segment focus
Exhibit 49: Bayer AG - Key offerings
Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 56: GlaxoSmithKline Plc - Vendor overview
Exhibit 57: GlaxoSmithKline Plc - Business segments
Exhibit 58: GlaxoSmithKline Plc - Organizational developments
Exhibit 59: GlaxoSmithKline Plc - Geographic focus
Exhibit 60: GlaxoSmithKline Plc - Segment focus
Exhibit 61: GlaxoSmithKline Plc - Key offerings
Exhibit 62: Novartis AG - Vendor overview
Exhibit 63: Novartis AG - Business segments
Exhibit 64: Novartis AG - Organizational developments
Exhibit 65: Novartis AG - Geographic focus
Exhibit 66: Novartis AG - Segment focus
Exhibit 67: Novartis AG - Key offerings
Exhibit 68: Pfizer Inc. - Vendor overview
Exhibit 69: Pfizer Inc. - Business segments
Exhibit 70: Pfizer Inc. - Organizational developments
Exhibit 71: Pfizer Inc. - Geographic focus
Exhibit 72: Pfizer Inc. - Segment focus
Exhibit 73: Pfizer Inc. - Key offerings
Exhibit 74: Validation techniques employed for market sizing
Exhibit 75: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- MORE
The following companies are recognised as the key players in the global neglected tropical disease treatment market: Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, and Pfizer Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development and approval of therapeutics for neglected tropical diseases.”
According to the report, one of the major drivers for this market is the initiatives to increase awareness and access to medicines for neglected tropical diseases.
Further, the report states that one of the major factors hindering the growth of this market is the challenges associated with diagnosing neglected tropical diseases.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development and approval of therapeutics for neglected tropical diseases.”
According to the report, one of the major drivers for this market is the initiatives to increase awareness and access to medicines for neglected tropical diseases.
Further, the report states that one of the major factors hindering the growth of this market is the challenges associated with diagnosing neglected tropical diseases.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
Note: Product cover images may vary from those shown
LOADING...
